Sarepta Therapeutics, Inc. SRPT Business Segments — Clinical Trial Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept srpt:ClinicalTrialExpenses.
The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sarepta Therapeutics, Inc.'s business segments — clinical trial expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sarepta Therapeutics, Inc.'s business segments — clinical trial expenses?
- Sarepta Therapeutics, Inc. (SRPT) reported business segments — clinical trial expenses of $18.3M in Q1 2026.
- How has Sarepta Therapeutics, Inc.'s business segments — clinical trial expenses changed year-over-year?
- Sarepta Therapeutics, Inc.'s business segments — clinical trial expenses decreased by 44.8% year-over-year, from $33.15M to $18.3M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s business segments — clinical trial expenses?
- Over 3 years (2022 to 2025), Sarepta Therapeutics, Inc.'s business segments — clinical trial expenses has grown at a -2.8% compound annual growth rate (CAGR), from $135.84M to $124.65M.
- What does business segments — clinical trial expenses mean?
- Reflects the costs incurred for conducting clinical research and development trials within the segment. It provides insight into the segment's commitment to pipeline innovation and future product development.